ArticleInternational journal of clinical and experimental pathology2018
The expressions of YAP1, β-catenin and survivin in colon cancer tissues and their clinical significance.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 8 citations in OpenAlex.
- Article
- Oncolytic adenovirus-mediated dual knockdown of survivin and OCT4 improves therapeutic efficacy in esophageal cancer.Annals of translational medicine · 2023Article
- Article
- The role of YAP1 in survival prediction, immune modulation, and drug response: A pan-cancer perspective.Frontiers in immunology · 2022Article
- Chemoprevention by aspirin against inflammation-related colorectal cancer in mice.Journal of clinical biochemistry and nutrition · 2021Article
- Obatoclax, a Pan-BCL-2 Inhibitor, Downregulates Survivin to Induce Apoptosis in Human Colorectal Carcinoma Cells Via Suppressing WNT/β-catenin Signaling.International journal of molecular sciences · 2020Article
- Targeting Yes1 Associated Transcriptional Regulator Inhibits Hepatocellular Carcinoma Progression and Improves Sensitivity to Sorafenib: An in vitro and in vivo Study.OncoTargets and therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to evaluate the effects of YAP1, β-catenin, and survivin on the onset and progression of colon cancer, and to explore their correlations. The expressions of YAP1, β-catenin, and survivin in 106 colon cancer tissues and 55 normal colon mucosa tissues were measured by immunohistochemical assay. The correlations between their expressions and clinical and pathological characteristics were analyzed. The expression rates of YAP1, β-catenin, and survivin in colon cancer tissues were significantly higher than those in normal colon mucosa tissues (P<0.001). The expressions of YAP1, β-catenin, and survivin in colon cancer were correlated with neither gender nor age (P>0.05), but with the degree of differentiation, depth of invasion, lymph node metastasis and Duke's stage (P<0.05). Pearson's correlation analysis showed that the expressions of YAP1, β-catenin, and survivin in colon cancer tissues were all positively correlated (P<0.05). The overexpression of YAP1, β-catenin, and survivin played an important role in the onset and progression of colon cancer, providing reference value for prognosis prediction.
Indexed as
Identifiers
31949692PMC6963090W3007539813What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.